Enhancement of immunological activity of cpg-odn vehiculized in lyotropic liquid crystal carriers Maletto B, Alemandi

MALETTO, B.; ALLEMANDI, DANIEL; MORON GABRIEL; PISTORESI M. C.; PALMA, SANTIAGO

Tandil, Buenos Aires.

Congreso; Sociedad Argentina de Farmacologia Experimental. SAFE; 2008

SAFE - Sociedad Argentina de Farmacologia experimental

CpG-ODN (oligonucleotides containing unmethylated CpG in particular base context) is a new adjuvant for vaccines that unfortunately has shown reduced bioavailability owed mainly to lack of chemical stability. In this work, we evaluated the  adjuvant capacity of CpG-ODN incorporated into lamellar mesophases of lyotropic liquid crystals (coagels). For that, BALB/c mices were immunized (s.c.) three times during fifteen days (schedule: 0, 7 and 15) with a protein antigen (OVA, 60 ug/mice/dose) plus CpG-ODN (50ug/mice/dose) or OVA/CpGODN/ coagel. On day 21, we measured specific antibodies in plasma and specific cytokines in cell culture supernatants (ELISA). The measured titles (log10) were:IgG IgG1 IgG2aOVA/CpG-ODN 3,9±0,0 3,4±0,1 2,7±0,2OVA/CpG-ODN/coagel 5,1±0,0 4,4±0,1 3,8±0,2The levels of IFN-g were higher in animals immunized with OVA/CpG-ODN/coagel than in those immunized with OVA/CpG-ODN (p<0,005). These results indicate that CpGODN intensified the specific immune response when administered in coagels.